Fondazione Policlinico Universitario A. Gemelli
Welcome,         Profile    Billing    Logout  
 38 Trials 
43 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hohaus, Stefan
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
241
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
11/25
11/25
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Jan 2023 - Dec 2024: Data from trial for hematological malignancies
Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Recruiting
3
190
Europe
Radiotherapy, Radiotherapy plus Obinutuzumab
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Follicular Lymphoma
04/31
04/31
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/24
12/25
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Active, not recruiting
2
75
Europe
Ibrutinib, IMBRUVICA (commercial name)
Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.
DLBCL
07/24
07/27
SAKK 38/19, NCT04604067: Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

Active, not recruiting
2
260
Europe
Acalabrutinib
Swiss Group for Clinical Cancer Research
Diffuse Large B-cell Lymphoma
10/25
12/30
KCP-330-009, NCT02227251 / 2014-001977-15: Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Checkmark Approved in Taiwan as monotherapy for R/R DLBCL
Oct 2022 - Oct 2022: Approved in Taiwan as monotherapy for R/R DLBCL
Checkmark Submitted NDA in South Korea for rrDLBCL
Jan 2021 - Jan 2021: Submitted NDA in South Korea for rrDLBCL
Checkmark Subset analysis data from SADAL trial for r/r DLBCL at ASH 2020
More
Recruiting
2
244
Europe, Canada, US, RoW
Selinexor, KPT-330
Karyopharm Therapeutics Inc
Diffuse Large B-cell Lymphoma
04/27
11/27
NCT04600804: The Role of 18F-FDG-PET for Staging and Prognostication

Active, not recruiting
N/A
200
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
10/23
01/25
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting
N/A
80
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
03/25
03/25
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

Recruiting
N/A
200
Europe
Incyte Biosciences Italy S.r.l, Advice Pharma Group srl
DLBCL - Diffuse Large B Cell Lymphoma
06/25
06/27
NCT05819528: Primary Cardiac Lymphoma: Italian Multicenter Experience

Recruiting
N/A
43
Europe
Fondazione Italiana Linfomi - ETS
Primary Cardiac Lymphoma
04/26
06/26
NCT06156774: SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

Recruiting
N/A
130
Europe
Chimeric Antigen Receptor T-cells (CAR-T) therapy
Fondazione Italiana Linfomi - ETS, Kite, A Gilead Company
Non-hodgkin Lymphoma,B Cell
07/26
07/26
LA-HLH, NCT06585124: Flow Cytometry for the Study of T-Cell Populations in Hemophagocytic Lymphohistiocytosis Associated With Lymphomas

Recruiting
N/A
150
Europe
Flow Cytometry
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lymphoma, Hemophagocytic Lymphohistiocytoses
05/25
05/26
FIL_PlaLy, NCT06781359: Study on Plasmablastic Lymphoma Patients

Not yet recruiting
N/A
200
Europe
Fondazione Italiana Linfomi - ETS, AIL Roma - Italia, AIL Cuneo - Italia
Plasmablastic Lymphoma
02/28
02/28
CV_CANCER, NCT06664528: Cardiovascular Health in Adult Patients With Cancer Exposed to Cardiotoxic Therapies

Recruiting
N/A
300
Europe
ECHOCARDIOGRAPHY, ELECTROCARDIOGRAPHY (ECG), LABORATORY TESTS
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cardiac Toxicity, Cancer
11/28
12/28
MIMOSA, NCT05746858: Predictive Biomarkers Including miRNA-based Tumor Signatures in Diffuse Large B Cell Lymphoma (R/R DLBCL)

Not yet recruiting
N/A
300
Europe
no intervention (observational study)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Istituti Fisioterapici Ospitalieri, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale
Diffuse Large B Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
03/25
03/27
NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis

Recruiting
N/A
400
Europe
Treatment for clinical practise
Fondazione Italiana Linfomi ONLUS
Classical Hodgkin Lymphoma
01/26
01/26
Scambia, Giovanni
NCT04460807 / 2018-000693-30: Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer

Terminated
3
23
Europe
Exemestane, Mestane, Placebo oral tablet
Ente Ospedaliero Ospedali Galliera, Istituto Di Ricerche Farmacologiche Mario Negri, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Federation of Italian Cooperative Oncology Groups
Ovarian Cancer
04/23
04/23
NCT02584478 / 2021-003871-32: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

Active, not recruiting
3
294
Europe, US, RoW
AL3818, Anlotinib Hydrochloride, Anlotinib, Catequentinib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Daily Topotecan, Weekly Topotecan, Carboplatin, Paraplatin, Taxol
Advenchen Laboratories, LLC, Advenchen Laboratories, LLC
Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma
10/24
12/24
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
NUVOLA, NCT04261465: TRIAL Open-label Multicentre Study

Recruiting
2
35
Europe
Olaparib, Lynparza, Paclitaxel, Carboplatin
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
High Grade Serous Ovarian Cancer
12/20
12/22
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting
1/2
230
Europe, US, RoW
rezatapopt, PC14586, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79
PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
03/26
07/26
GO-VAC, NCT04584957: Prophylactic Negative Pressure Wound Therapy (VAC) in Gynecologic Oncology (G.O.)

Active, not recruiting
N/A
196
Europe
VAC therapy
Catholic University of the Sacred Heart
Wound Infection, Gynecologic Cancer
09/21
09/21
MYLUNAR, NCT04123158: MYometrial Lesion UltrasouNd And mRi

Completed
N/A
2353
Europe
Ultrasound, MRI
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Prof. Antonia Testa, Dr. Daniela Romualdi, Dr. Francesca Ciccarone
Sarcoma Uterus
12/23
12/23
CLESS, NCT04178876: Comparison of Laparoscopic Endometrioma Stripping Versus Ethanol Sclerotherapy( )

Recruiting
N/A
64
Europe
ethanol sclerotherapy, stripping technique
Catholic University of the Sacred Heart
Endometrioma
11/22
06/23
FPG-500, NCT06020625: Mutational Oncology in Clinical Practice

Recruiting
N/A
20000
Europe
Diagnostic Test
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Genome Instability, Genetic Predisposition to Disease, Gene Rearrangement
05/23
01/32
NCT04291612: Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease

Recruiting
N/A
1400
Europe, US, RoW
Physical exam
Memorial Sloan Kettering Cancer Center
Endometrial Cancer, Endometrioid Adenocarcinoma, Endometrial Cancer Stage I
02/25
02/25
R-LYNUS, NCT06621823: Image-guided Ultrasound Robotic Intraoperative Evaluation of Lymph-nodes Status in Gynecological Malignancies

Recruiting
N/A
160
Europe
image-guided surgery technique
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lymph Node Metastasis, Gynecologic Cancer
12/24
05/26
G-AYA, NCT06594471: Comprehensive Assessment of Clinical Characteristics and Outcomes of Gemelli Adolescents and Young Adults

Not yet recruiting
N/A
500
Europe
Questionnaire on late-term physical effects, Questionnaire on sexual and reproductive health outcomes, Questionnaire on psychological outcomes, Questionnaire on social outcomes
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Gynecologic Cancer
09/39
03/40
LYSE, NCT06619002: Implementation of Surgical Safety and Intraoperative Metastasis Identification Through Deep Learning: Multicentric Video Collection for Minimally Invasive Sentinel Lymph Node Dissection in Uterine Malignancies

Recruiting
N/A
100
Europe
Sentinel lymph node sampling, sentinel lymph node detection, sentinel lymph node dissection, sentinel lymph node biopsy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, IHU Strasbourg, University Hospital, Strasbourg
Endometrial Cancer, Cervical Cancer, Deep Learning, Artificial Intelligence
09/26
09/27
LASH, NCT06416748: Minimally Invasive Simple Hysterectomy in Low Risk Cervical Cancer

Recruiting
N/A
974
Europe
Minimally invasive simple hysterectomy, simple hysterectomy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cervical Cancer, Cervix Cancer
07/27
07/30
GEN&RARE, NCT06926127: Genomic Profiling of Genetic and Rare Diseases

Recruiting
N/A
1500
Europe
Whole Exome Sequencing (WES)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rare Diseases, Genetic Disease
04/26
02/30
Immuno-Gyn, NCT06737640: Evaluation of Clinical and Molecular Biomarkers in Immunotherapy Treatment in Gynecologic Cancer

Not yet recruiting
N/A
90
Europe
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cervical Cancer, Endometrial Cancer
12/25
12/26
SOLAR, NCT06832397: Detection of Peritoneal Metastases by Diagnostic LAparoscopy in Patients With Locally Advanced Cervical Carcinoma

Not yet recruiting
N/A
120
Europe
Diagnostic laparoscopy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cervical Cancer
02/28
02/31
STORY, NCT06802198: A Randomized Study Comparing Subtotal vs Total Hysterectomy Long Term Outcomes

Not yet recruiting
N/A
500
Europe
total hysterectomy, subtotal hysterectomy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Fibroid Uterus, Metrorrhagia, Adenomyosis, Benign Gynecologic Neoplasm, Endometriosis, Abnormal Uterine Bleeding
02/28
02/30
IMMUNO_ASSAY, NCT06797479: Detection of Circulating Therapeutic Monoclonal Antibodies in Biological Samples of Gynecological Cancer Patients.

Not yet recruiting
N/A
12
NA
Blood samples for the analysis of sildenafil in plasma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Gynecological Cancer, Immunotherapy
03/30
12/30
MIPEX, NCT06867445: Minimally Invasive Pelvic Exenteration in Vaginal or Cervical Cancer Recurrence

Recruiting
N/A
64
Europe
Minimally invasive pelvic exenteration
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cervical Cancers, Vaginal Cancers
03/28
03/31
TAILOR, NCT04555473: Translational Analysis In Longitudinal Series of Ovarian Cancer ORganoids

Recruiting
N/A
48
Europe
Tumor biopsy, Blood sampling
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Organoids, Epithelial Ovarian Cancer
11/21
05/23
Iezzi, Roberto
BIOPEARL-ONE, NCT05911633: BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)

Suspended
N/A
50
Europe
BioPearl™
Terumo Europe N.V.
Hepatocellular Carcinoma Non-resectable
06/26
11/27
Pedicelli, Alessandro
IMPACT, NCT04572230: International Post Market Surveillance Study of Intracranial Aneurysms Treated With an Endovascular Approach

Active, not recruiting
N/A
405
Europe
Endovascular treatment of intracranial aneurysms using a flow-diverting stent
Stryker Neurovascular
Intracranial Aneurysm
09/24
09/25
Valente, Iacopo
IMPACT, NCT04572230: International Post Market Surveillance Study of Intracranial Aneurysms Treated With an Endovascular Approach

Active, not recruiting
N/A
405
Europe
Endovascular treatment of intracranial aneurysms using a flow-diverting stent
Stryker Neurovascular
Intracranial Aneurysm
09/24
09/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Hohaus, Stefan
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
241
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
11/25
11/25
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Jan 2023 - Dec 2024: Data from trial for hematological malignancies
Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Recruiting
3
190
Europe
Radiotherapy, Radiotherapy plus Obinutuzumab
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Follicular Lymphoma
04/31
04/31
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/24
12/25
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Active, not recruiting
2
75
Europe
Ibrutinib, IMBRUVICA (commercial name)
Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.
DLBCL
07/24
07/27
SAKK 38/19, NCT04604067: Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.

Active, not recruiting
2
260
Europe
Acalabrutinib
Swiss Group for Clinical Cancer Research
Diffuse Large B-cell Lymphoma
10/25
12/30
KCP-330-009, NCT02227251 / 2014-001977-15: Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Checkmark Approved in Taiwan as monotherapy for R/R DLBCL
Oct 2022 - Oct 2022: Approved in Taiwan as monotherapy for R/R DLBCL
Checkmark Submitted NDA in South Korea for rrDLBCL
Jan 2021 - Jan 2021: Submitted NDA in South Korea for rrDLBCL
Checkmark Subset analysis data from SADAL trial for r/r DLBCL at ASH 2020
More
Recruiting
2
244
Europe, Canada, US, RoW
Selinexor, KPT-330
Karyopharm Therapeutics Inc
Diffuse Large B-cell Lymphoma
04/27
11/27
NCT04600804: The Role of 18F-FDG-PET for Staging and Prognostication

Active, not recruiting
N/A
200
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
10/23
01/25
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting
N/A
80
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
03/25
03/25
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

Recruiting
N/A
200
Europe
Incyte Biosciences Italy S.r.l, Advice Pharma Group srl
DLBCL - Diffuse Large B Cell Lymphoma
06/25
06/27
NCT05819528: Primary Cardiac Lymphoma: Italian Multicenter Experience

Recruiting
N/A
43
Europe
Fondazione Italiana Linfomi - ETS
Primary Cardiac Lymphoma
04/26
06/26
NCT06156774: SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project

Recruiting
N/A
130
Europe
Chimeric Antigen Receptor T-cells (CAR-T) therapy
Fondazione Italiana Linfomi - ETS, Kite, A Gilead Company
Non-hodgkin Lymphoma,B Cell
07/26
07/26
LA-HLH, NCT06585124: Flow Cytometry for the Study of T-Cell Populations in Hemophagocytic Lymphohistiocytosis Associated With Lymphomas

Recruiting
N/A
150
Europe
Flow Cytometry
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lymphoma, Hemophagocytic Lymphohistiocytoses
05/25
05/26
FIL_PlaLy, NCT06781359: Study on Plasmablastic Lymphoma Patients

Not yet recruiting
N/A
200
Europe
Fondazione Italiana Linfomi - ETS, AIL Roma - Italia, AIL Cuneo - Italia
Plasmablastic Lymphoma
02/28
02/28
CV_CANCER, NCT06664528: Cardiovascular Health in Adult Patients With Cancer Exposed to Cardiotoxic Therapies

Recruiting
N/A
300
Europe
ECHOCARDIOGRAPHY, ELECTROCARDIOGRAPHY (ECG), LABORATORY TESTS
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cardiac Toxicity, Cancer
11/28
12/28
MIMOSA, NCT05746858: Predictive Biomarkers Including miRNA-based Tumor Signatures in Diffuse Large B Cell Lymphoma (R/R DLBCL)

Not yet recruiting
N/A
300
Europe
no intervention (observational study)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Istituti Fisioterapici Ospitalieri, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale
Diffuse Large B Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
03/25
03/27
NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis

Recruiting
N/A
400
Europe
Treatment for clinical practise
Fondazione Italiana Linfomi ONLUS
Classical Hodgkin Lymphoma
01/26
01/26
Scambia, Giovanni
NCT04460807 / 2018-000693-30: Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer

Terminated
3
23
Europe
Exemestane, Mestane, Placebo oral tablet
Ente Ospedaliero Ospedali Galliera, Istituto Di Ricerche Farmacologiche Mario Negri, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Federation of Italian Cooperative Oncology Groups
Ovarian Cancer
04/23
04/23
NCT02584478 / 2021-003871-32: Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)

Active, not recruiting
3
294
Europe, US, RoW
AL3818, Anlotinib Hydrochloride, Anlotinib, Catequentinib, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan, Daily Topotecan, Weekly Topotecan, Carboplatin, Paraplatin, Taxol
Advenchen Laboratories, LLC, Advenchen Laboratories, LLC
Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Cervical Carcinoma
10/24
12/24
FLORA-4, NCT04498117 / 2020-002270-26: Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Active, not recruiting
3
615
Europe, Canada, US, RoW
Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo
CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd
Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
09/25
08/27
NUVOLA, NCT04261465: TRIAL Open-label Multicentre Study

Recruiting
2
35
Europe
Olaparib, Lynparza, Paclitaxel, Carboplatin
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
High Grade Serous Ovarian Cancer
12/20
12/22
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting
1/2
230
Europe, US, RoW
rezatapopt, PC14586, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79
PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (Non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
03/26
07/26
GO-VAC, NCT04584957: Prophylactic Negative Pressure Wound Therapy (VAC) in Gynecologic Oncology (G.O.)

Active, not recruiting
N/A
196
Europe
VAC therapy
Catholic University of the Sacred Heart
Wound Infection, Gynecologic Cancer
09/21
09/21
MYLUNAR, NCT04123158: MYometrial Lesion UltrasouNd And mRi

Completed
N/A
2353
Europe
Ultrasound, MRI
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Prof. Antonia Testa, Dr. Daniela Romualdi, Dr. Francesca Ciccarone
Sarcoma Uterus
12/23
12/23
CLESS, NCT04178876: Comparison of Laparoscopic Endometrioma Stripping Versus Ethanol Sclerotherapy( )

Recruiting
N/A
64
Europe
ethanol sclerotherapy, stripping technique
Catholic University of the Sacred Heart
Endometrioma
11/22
06/23
FPG-500, NCT06020625: Mutational Oncology in Clinical Practice

Recruiting
N/A
20000
Europe
Diagnostic Test
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Genome Instability, Genetic Predisposition to Disease, Gene Rearrangement
05/23
01/32
NCT04291612: Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease

Recruiting
N/A
1400
Europe, US, RoW
Physical exam
Memorial Sloan Kettering Cancer Center
Endometrial Cancer, Endometrioid Adenocarcinoma, Endometrial Cancer Stage I
02/25
02/25
R-LYNUS, NCT06621823: Image-guided Ultrasound Robotic Intraoperative Evaluation of Lymph-nodes Status in Gynecological Malignancies

Recruiting
N/A
160
Europe
image-guided surgery technique
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lymph Node Metastasis, Gynecologic Cancer
12/24
05/26
G-AYA, NCT06594471: Comprehensive Assessment of Clinical Characteristics and Outcomes of Gemelli Adolescents and Young Adults

Not yet recruiting
N/A
500
Europe
Questionnaire on late-term physical effects, Questionnaire on sexual and reproductive health outcomes, Questionnaire on psychological outcomes, Questionnaire on social outcomes
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Gynecologic Cancer
09/39
03/40
LYSE, NCT06619002: Implementation of Surgical Safety and Intraoperative Metastasis Identification Through Deep Learning: Multicentric Video Collection for Minimally Invasive Sentinel Lymph Node Dissection in Uterine Malignancies

Recruiting
N/A
100
Europe
Sentinel lymph node sampling, sentinel lymph node detection, sentinel lymph node dissection, sentinel lymph node biopsy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, IHU Strasbourg, University Hospital, Strasbourg
Endometrial Cancer, Cervical Cancer, Deep Learning, Artificial Intelligence
09/26
09/27
LASH, NCT06416748: Minimally Invasive Simple Hysterectomy in Low Risk Cervical Cancer

Recruiting
N/A
974
Europe
Minimally invasive simple hysterectomy, simple hysterectomy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cervical Cancer, Cervix Cancer
07/27
07/30
GEN&RARE, NCT06926127: Genomic Profiling of Genetic and Rare Diseases

Recruiting
N/A
1500
Europe
Whole Exome Sequencing (WES)
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rare Diseases, Genetic Disease
04/26
02/30
Immuno-Gyn, NCT06737640: Evaluation of Clinical and Molecular Biomarkers in Immunotherapy Treatment in Gynecologic Cancer

Not yet recruiting
N/A
90
Europe
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cervical Cancer, Endometrial Cancer
12/25
12/26
SOLAR, NCT06832397: Detection of Peritoneal Metastases by Diagnostic LAparoscopy in Patients With Locally Advanced Cervical Carcinoma

Not yet recruiting
N/A
120
Europe
Diagnostic laparoscopy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cervical Cancer
02/28
02/31
STORY, NCT06802198: A Randomized Study Comparing Subtotal vs Total Hysterectomy Long Term Outcomes

Not yet recruiting
N/A
500
Europe
total hysterectomy, subtotal hysterectomy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Fibroid Uterus, Metrorrhagia, Adenomyosis, Benign Gynecologic Neoplasm, Endometriosis, Abnormal Uterine Bleeding
02/28
02/30
IMMUNO_ASSAY, NCT06797479: Detection of Circulating Therapeutic Monoclonal Antibodies in Biological Samples of Gynecological Cancer Patients.

Not yet recruiting
N/A
12
NA
Blood samples for the analysis of sildenafil in plasma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Gynecological Cancer, Immunotherapy
03/30
12/30
MIPEX, NCT06867445: Minimally Invasive Pelvic Exenteration in Vaginal or Cervical Cancer Recurrence

Recruiting
N/A
64
Europe
Minimally invasive pelvic exenteration
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cervical Cancers, Vaginal Cancers
03/28
03/31
TAILOR, NCT04555473: Translational Analysis In Longitudinal Series of Ovarian Cancer ORganoids

Recruiting
N/A
48
Europe
Tumor biopsy, Blood sampling
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Organoids, Epithelial Ovarian Cancer
11/21
05/23
Iezzi, Roberto
BIOPEARL-ONE, NCT05911633: BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)

Suspended
N/A
50
Europe
BioPearl™
Terumo Europe N.V.
Hepatocellular Carcinoma Non-resectable
06/26
11/27
Pedicelli, Alessandro
IMPACT, NCT04572230: International Post Market Surveillance Study of Intracranial Aneurysms Treated With an Endovascular Approach

Active, not recruiting
N/A
405
Europe
Endovascular treatment of intracranial aneurysms using a flow-diverting stent
Stryker Neurovascular
Intracranial Aneurysm
09/24
09/25
Valente, Iacopo
IMPACT, NCT04572230: International Post Market Surveillance Study of Intracranial Aneurysms Treated With an Endovascular Approach

Active, not recruiting
N/A
405
Europe
Endovascular treatment of intracranial aneurysms using a flow-diverting stent
Stryker Neurovascular
Intracranial Aneurysm
09/24
09/25

Download Options